Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Alright. Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Malcolm Kuno, Priyanka Grover, [Gloria Hall].
Our next presenting company is Apellis. And presenting on behalf of the company, we have CEO, Cedric Francois.
Thank you so much, Anupam, and thank you for inviting us again to speak here. It's great to see many familiar faces. Let's dive straight into what is a special year that we have in front of us after 2023, which all of you know had quite a bit of tumultuous events in it. I will be making some forward-looking statements.
And I want to start off with this slide, which reminds us of what we really do at Apellis, where we combine courageous science with compassion. And that has resulted in 2 approved drugs since our time when we went public in 2017,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
